Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $280.00 by Analysts at Royal Bank Of Canada

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target decreased by equities research analysts at Royal Bank Of Canada from $345.00 to $280.00 in a research note issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s target price would indicate a potential upside of 65.78% from the company’s current price.

ALNY has been the topic of several other research reports. Chardan Capital reaffirmed a “buy” rating and set a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, July 31st. Jefferies Financial Group raised their target price on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research note on Tuesday, September 8th. Citigroup dropped their price objective on Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. Stifel Nicolaus lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price target for the company. in a research note on Thursday. Finally, HC Wainwright reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $331.38.

Alnylam Pharmaceuticals Stock Down 2.9%

NASDAQ:ALNY traded down $5.10 on Friday, hitting $168.90. The stock had a trading volume of 1,544,875 shares, compared to its average volume of 1,492,568. The stock has a market cap of $22.60 billion, a P/E ratio of 31.13 and a beta of 0.28. Alnylam Pharmaceuticals has a 1 year low of $168.80 and a 1 year high of $479.79. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The firm’s fifty day simple moving average is $237.78 and its two-hundred day simple moving average is $287.22.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same period in the previous year, the business posted $2.90 EPS. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals will post 6.43 earnings per share for the current year.

Insider Activity

In related news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Toth Financial Advisory Corp purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth $25,000. Keating Financial Advisory Services Inc. purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $42,000. Burkett Financial Services LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at $37,000. CoreCap Advisors LLC increased its position in Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 134 shares during the last quarter. Finally, Ascentis Independent Advisors bought a new position in Alnylam Pharmaceuticals in the first quarter valued at about $64,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Key Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Third-quarter revenue rose 16.7% year over year to $1.46 billion, exceeding the $1.43 billion consensus estimate. Reported EPS of $16.26 also surpassed expectations, although the result was significantly boosted by a roughly $1.9 billion tax benefit. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Management reaffirmed its fiscal 2026 outlook and anticipates $4.2 billion to $4.5 billion in TTR product sales, supporting the company’s near-term revenue base. Alnylam TTR sales outlook and TRITON-CM expansion
• Positive Sentiment: Needham maintained a “buy” rating, with a reduced $243 price target that still implies substantial upside, while Alnylam highlighted continued progress across its RNAi pipeline. Needham analyst rating
• Neutral Sentiment: Alnylam expanded the Phase 3 TRITON-CM study of nucresiran to approximately 2,250 patients while retaining an expected launch timeline around 2030. The larger trial may improve the evidence base but also raises development costs and reinforces the long wait for a potential revenue contribution. Alnylam pipeline and nucresiran update
• Negative Sentiment: Investors reacted negatively to indications that U.S. Amvuttra and Onpattro sales growth is slowing, reducing the impact of the earnings beat and raising concerns about the pace of future growth. Alnylam sales growth analysis
• Negative Sentiment: Stifel downgraded ALNY from “buy” to “hold” with a $225 target, followed by Bernstein’s downgrade from “outperform” to “market perform” with a $199 target. Although both targets remain above the recent trading level, the rating changes signal reduced conviction and added selling pressure. Stifel downgrade

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.